The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations

Am J Obstet Gynecol. 2021 May;224(5):484-495. doi: 10.1016/j.ajog.2021.01.022. Epub 2021 Jan 30.

Abstract

The coronavirus disease 2019 has caused over 2 million deaths worldwide, with over 412,000 deaths reported in Unites States. To date, at least 57,786 pregnant women in the United States have been infected, and 71 pregnant women have died. Although pregnant women are at higher risk of severe coronavirus disease 2019-related illness, clinical trials for the available vaccines excluded pregnant and lactating women. The safety and efficacy of the vaccines for pregnant women, the fetus, and the newborn remain unknown. A review of maternal and neonatal coronavirus disease 2019 morbidity and mortality data along with perinatal vaccine safety considerations are presented to assist providers with shared decision-making regarding vaccine administration for this group, including the healthcare worker who is pregnant, lactating, or considering pregnancy. The coronavirus disease 2019 vaccine should be offered to pregnant women after discussing the lack of safety data, with preferential administration for those at highest risk of severe infection, until safety and efficacy of these novel vaccines are validated.

Keywords: COVID-19 vaccine; Middle East respiratory syndrome; Zika; coronavirus; coronavirus disease 2019; influenza A H1N1; lactation; mRNA vaccine; maternal immunity; severe acute respiratory syndrome; severe acute respiratory syndrome coronavirus 2; vaccine safety.

Publication types

  • Review

MeSH terms

  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / adverse effects
  • COVID-19 Vaccines / immunology*
  • Female
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control
  • Pregnancy
  • Pregnancy Complications, Infectious / prevention & control*
  • SARS-CoV-2 / immunology*
  • Vaccination*

Substances

  • COVID-19 Vaccines